The American Diabetes Association has issued a guidance statement that cautions against using compounded versions of popular GLP-1 diabetes and weight-loss drugs such as Wegovy and Zepbound.
According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs for Medicare, but this could have a big effect on all employers health plans as well.